ARCH Venture Management, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), ARCH Venture Management, LLC reported 9 stock positions worth $206.2 million. Its top holding was Beam Therapeutics (BEAM) at 43.0% of the portfolio, followed by Maze Therapeutics (MAZE, 22.0%) and Rapport Therapeutics (RAPP, 18.2%). Compared with Q4 2024, it opened 1 new position, sold out of 1 and reduced 1. The biggest buy was a new position in Maze Therapeutics (MAZE) and the biggest sale an exit from Singular Genomics Systems (OMIC).
- Most Recent 13F
- Q2 2026
- Location
- CHICAGO, IL
- CIK
- 0001274403
- Portfolio Value
- $206.2M (Q1 2025)
- SEC Filing
- 0001012975-25-000245 ↗ filed May 15, 2025
Holdings Value
Holdings 9 stocks · $206.2M
| BEAM Beam Therapeutics Inc. | 43.00% | 4,540,132 | $88.7M | No change |
| MAZE Maze Therapeutics Inc. | 22.00% | 4,120,053 | $45.4M | New |
| RAPP Rapport Therapeutics Inc. | 18.21% | 3,728,738 | $37.5M | No change |
| ERAS Erasca Inc. | 7.34% | 11,055,554 | $15.1M | No change |
| VERV Verve Therapeutics Inc. | 4.42% | 2,008,809 | $9.1M | No change |
| GOSS Gossamer Bio Inc. | 4.26% | 8,055,916 | $8.8M | No change |
| UNBX Unity Biotechnology Inc. | 0.51% | 1,004,817 | $1.0M | No change |
| QTTB Q32 Bio Inc. | 0.26% | 320,482 | $532K | No change |
| CERO THERAPEUTICS HLDGS INC | 0.01% | 22,102 | $16K | Reduce -76.5% |
Portfolio Sells Q4 2024 → Q1 2025
| OMIC Singular Genomics Systems Inc. | Sold out | 0.00% | −1.07 |
| CERO THERAPEUTICS HLDGS INC | Reduce -76.5% | 0.01% | −0.24 |
Portfolio Buys Q4 2024 → Q1 2025
| MAZE Maze Therapeutics Inc. | New | 22.00% | +22.00 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.1B | PBLS, BEAM, RAPP, SPTX, ERAS |
| Q1 2026 | 10 | $677.1M | MAZE, RAPP, VIR, ERAS, BEAM |
| Q4 2025 | 9 | $651.7M | MAZE, BEAM, RAPP, LYEL, VIR |
| Q3 2025 | 9 | $492.4M | RAPP, BEAM, MAZE, VIR, LYEL |
| Q2 2025 | 11 | $299.1M | BEAM, VIR, MAZE, RAPP, VERV |
| Q1 2025 | 9 | $206.2M | BEAM, MAZE, RAPP, ERAS, VERV |
| Q4 2024 | 9 | $230.2M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q3 2024 | 9 | $260.6M | BEAM, RAPP, ERAS, QTTB, VERV |
| Q2 2024 | 9 | $266.0M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q1 2024 | 8 | $80.3M | VERV, ERAS, GOSS, DNLI, QTTB |